发明名称 Controlled release hydromorphone composition
摘要 A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37 DEG C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% ad 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
申请公布号 US4844909(A) 申请公布日期 1989.07.04
申请号 US19870113865 申请日期 1987.10.26
申请人 EUROCELTIQUE, S.A. 发明人 GOLDIE, ROBERT S.;MALKOWSKA, SANDRA T. A.;LESLIE, STEWART T.;MILLER, RONALD B.
分类号 A61K9/28;A61K9/16;A61K9/20;A61K9/22;A61K9/36;A61K9/50;A61K31/485;A61K47/00;A61K47/38 主分类号 A61K9/28
代理机构 代理人
主权项
地址
您可能感兴趣的专利